H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $138 from $145 and keeps a Buy rating on the shares after the company entered into a definitive purchase agreement with CureVac (CVAC). The firm views the acquisition as “incrementally positive,” saying removes a litigation headwind for BioNTech, strengthens the company’s mRNA patent portfolio, and expands BioNTech’s manufacturing capability.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech SE’s Strategic Acquisition of CureVac Bolsters mRNA Therapeutics and Growth Potential
- BioNTech’s Strategic Acquisition of CureVac: Enhancing mRNA Platform and Market Position
- Strategic Acquisition and Pipeline Synergies Drive Buy Rating for BioNTech
- BioNTech’s Strategic Acquisition of CureVac: Enhancing Oncology Focus and Expanding mRNA Portfolio
- BioNTech Announces Strategic Acquisition of CureVac